Celldex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Celldex Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 1.1% bzw. 74.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -169.5% betragen.

Wichtige Informationen

1.1%

Wachstumsrate der Gewinne

5.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	74.8%
Zukünftige Eigenkapitalrendite	-169.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CLDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3	-266	-234	-190	7
12/31/2025	4	-223	-165	-170	10
12/31/2024	7	-160	-157	-143	10
9/30/2024	10	-154	-160	-158	N/A
6/30/2024	8	-150	-123	-121	N/A
3/31/2024	6	-145	-121	-119	N/A
12/31/2023	7	-141	-109	-107	N/A
9/30/2023	4	-125	-98	-97	N/A
6/30/2023	3	-113	-114	-113	N/A
3/31/2023	3	-119	-110	-108	N/A
12/31/2022	2	-112	-106	-104	N/A
9/30/2022	1	-106	-98	-96	N/A
6/30/2022	1	-100	-79	-78	N/A
3/31/2022	4	-77	-69	-67	N/A
12/31/2021	5	-71	-62	-61	N/A
9/30/2021	8	-72	-53	-52	N/A
6/30/2021	9	-66	-48	-47	N/A
3/31/2021	5	-64	-48	-46	N/A
12/31/2020	7	-60	-42	-40	N/A
9/30/2020	5	-48	-48	-46	N/A
6/30/2020	4	-46	-47	-45	N/A
3/31/2020	5	-46	-46	-45	N/A
12/31/2019	4	-51	-47	-46	N/A
9/30/2019	4	-50	-52	-51	N/A
6/30/2019	5	-46	-55	-54	N/A
3/31/2019	7	-50	-61	-60	N/A
12/31/2018	10	-151	-76	-75	N/A
9/30/2018	11	-146	-80	-79	N/A
6/30/2018	14	-165	N/A	-89	N/A
3/31/2018	15	-177	N/A	-93	N/A
12/31/2017	13	-93	N/A	-100	N/A
9/30/2017	11	-121	N/A	-101	N/A
6/30/2017	9	-125	N/A	-100	N/A
3/31/2017	7	-128	N/A	-113	N/A
12/31/2016	7	-129	N/A	-113	N/A
9/30/2016	7	-129	N/A	-106	N/A
6/30/2016	6	-131	N/A	-110	N/A
3/31/2016	6	-132	N/A	-101	N/A
12/31/2015	5	-127	N/A	-99	N/A
9/30/2015	5	-126	N/A	-107	N/A
6/30/2015	5	-122	N/A	-106	N/A
3/31/2015	4	-118	N/A	-102	N/A
12/31/2014	4	-118	N/A	-102	N/A
9/30/2014	3	-108	N/A	-94	N/A
6/30/2014	3	-103	N/A	-85	N/A
3/31/2014	2	-94	N/A	-82	N/A
12/31/2013	4	-82	N/A	-68	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CLDXDie Einnahmen des Unternehmens (74.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: CLDXDie Einnahmen des Unternehmens (74.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLDX wird voraussichtlich in 3 Jahren unrentabel sein.

Celldex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 65%

Consensus revenue estimates increase by 65%, EPS downgraded

Price target decreased by 7.6% to US$65.38

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target increased by 9.7% to US$69.43

Consensus revenue estimates increase by 37%, EPS downgraded

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Consensus revenue estimates increase by 37%, EPS downgraded

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.4% to US$64.00

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

Price target decreased by 7.4% to US$59.57

Consensus revenue estimates decrease by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Now 20% undervalued after recent price drop

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

Consensus revenue estimates increase by 68%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Now 23% undervalued

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Founder exercised options and sold US$576k worth of stock

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Senior VP notifies of intention to sell stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022